Format

Send to

Choose Destination
JACC Cardiovasc Interv. 2014 Aug;7(8):875-81. doi: 10.1016/j.jcin.2014.01.171.

Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients.

Author information

1
Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: m.swaans@antoniusziekenhuis.nl.
2
Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
3
Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.

Abstract

OBJECTIVES:

The goal of this study was to compare survival between transcatheter mitral valve (MV) repair using MitraClip system (Abbott Vascular, Santa Clara, California), MV-surgery, and conservative treatment in high-surgical-risk patients symptomatic with severe mitral valve regurgitation (MR).

BACKGROUND:

Up to 50% of patients with symptomatic severe MR are denied for surgery due to high perioperative risk. Transcatheter MV repair might be an alternative.

METHODS:

Consecutive patients (n = 139) treated with transcatheter MV repair were included. Comparator surgically (n = 53) and conservatively (n = 59) treated patients were identified retrospectively. Surgical risk was based on the logistic European System for Cardiac Operative Risk Evaluation (log EuroSCORE) or the presence of relevant risk factors, as judged by the heart team.

RESULTS:

The log EuroSCORE was higher in the transcatheter MV repair group (23.9 ± 16.1%) than in the surgically (14.2 ± 8.9%) and conservatively (18.7 ± 13.2%, p < 0.0001) treated patients. Left ventricular ejection fraction was higher in surgical patients (43.9 ± 14.4%, p = 0.003), with similar values for the transcatheter MV repair (36.8 ± 15.3%) and conservatively treated (34.5 ± 16.5%) groups. After 1 year of follow-up, the transcatheter MV repair and surgery groups showed similar survival rates (85.8% and 85.2%, respectively), whereas 67.7% of conservatively treated patients survived. The same trend was observed after the second and third years. After weighting for propensity score and controlling for risk factors, both the transcatheter MV repair (hazard ratio [HR]: 0.41, 95% confidence interval [CI]: 0.22 to 0.78, p = 0.006) and surgical (HR: 0.52, 95% CI: 0.30 to 0.88, p = 0.014) groups showed better survival than the conservatively treated group. The transcatheter MV repair and surgical groups did not differ (HR: 1.25, 95% CI: 0.72 to 2.16, p = 0.430).

CONCLUSIONS:

Despite a higher log EuroSCORE, high-surgical-risk patients with symptomatic severe MR treated with transcatheter MV repair show similar survival rates compared with surgically treated patients, with both displaying survival benefit compared with conservative treatment.

KEYWORDS:

heart failure; mitral valve; mortality; valvuloplasty

PMID:
25147032
DOI:
10.1016/j.jcin.2014.01.171
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center